JP6757935B2 - 分子マンモグラフィ - Google Patents
分子マンモグラフィ Download PDFInfo
- Publication number
- JP6757935B2 JP6757935B2 JP2016570087A JP2016570087A JP6757935B2 JP 6757935 B2 JP6757935 B2 JP 6757935B2 JP 2016570087 A JP2016570087 A JP 2016570087A JP 2016570087 A JP2016570087 A JP 2016570087A JP 6757935 B2 JP6757935 B2 JP 6757935B2
- Authority
- JP
- Japan
- Prior art keywords
- mir
- breast
- individual
- use according
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000009607 mammography Methods 0.000 title claims description 100
- 239000012530 fluid Substances 0.000 claims description 157
- 210000000481 breast Anatomy 0.000 claims description 123
- 238000000034 method Methods 0.000 claims description 97
- 108091070501 miRNA Proteins 0.000 claims description 88
- 239000002679 microRNA Substances 0.000 claims description 88
- 230000005856 abnormality Effects 0.000 claims description 40
- -1 elibrin Chemical compound 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 38
- 229940124597 therapeutic agent Drugs 0.000 claims description 36
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 32
- 230000003902 lesion Effects 0.000 claims description 32
- 210000002445 nipple Anatomy 0.000 claims description 29
- 230000007067 DNA methylation Effects 0.000 claims description 28
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 28
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 26
- 239000000090 biomarker Substances 0.000 claims description 21
- 229960004679 doxorubicin Drugs 0.000 claims description 16
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 16
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 15
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 15
- 101800000989 Oxytocin Proteins 0.000 claims description 13
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 13
- 229930012538 Paclitaxel Natural products 0.000 claims description 13
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 13
- 229960001723 oxytocin Drugs 0.000 claims description 13
- 229960001592 paclitaxel Drugs 0.000 claims description 13
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 13
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 12
- 229960004397 cyclophosphamide Drugs 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229960001603 tamoxifen Drugs 0.000 claims description 10
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 9
- 229960001904 epirubicin Drugs 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 8
- 108091029500 miR-183 stem-loop Proteins 0.000 claims description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
- 108010066816 Polypeptide N-acetylgalactosaminyltransferase Proteins 0.000 claims description 7
- 229960002949 fluorouracil Drugs 0.000 claims description 7
- 108091049679 miR-20a stem-loop Proteins 0.000 claims description 7
- 229960000575 trastuzumab Drugs 0.000 claims description 7
- NYDCDZSEEAUOHN-IZHYLOQSSA-N N-Desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=CC=C1 NYDCDZSEEAUOHN-IZHYLOQSSA-N 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091091751 miR-17 stem-loop Proteins 0.000 claims description 6
- 108091031103 miR-181a stem-loop Proteins 0.000 claims description 6
- 108091046591 miR-181a-4 stem-loop Proteins 0.000 claims description 6
- 108091049627 miR-181a-5 stem-loop Proteins 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 5
- 229960002932 anastrozole Drugs 0.000 claims description 5
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 5
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- 229960000255 exemestane Drugs 0.000 claims description 5
- 239000012022 methylating agents Substances 0.000 claims description 5
- 108091058688 miR-141 stem-loop Proteins 0.000 claims description 5
- 108091063348 miR-193 stem-loop Proteins 0.000 claims description 5
- 108091036762 miR-193a stem-loop Proteins 0.000 claims description 5
- 108091039097 miR-193b stem-loop Proteins 0.000 claims description 5
- 108091063344 miR-30b stem-loop Proteins 0.000 claims description 5
- 108091057431 miR-30d stem-loop Proteins 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229940125944 selective estrogen receptor degrader Drugs 0.000 claims description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 4
- 108091007774 MIR107 Proteins 0.000 claims description 4
- 108091007772 MIRLET7C Proteins 0.000 claims description 4
- 108091027766 Mir-143 Proteins 0.000 claims description 4
- 108091028684 Mir-145 Proteins 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960005167 everolimus Drugs 0.000 claims description 4
- 238000001125 extrusion Methods 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 229960001320 lapatinib ditosylate Drugs 0.000 claims description 4
- 108091044046 miR-17-1 stem-loop Proteins 0.000 claims description 4
- 108091065423 miR-17-3 stem-loop Proteins 0.000 claims description 4
- 108091089775 miR-200b stem-loop Proteins 0.000 claims description 4
- 108091092722 miR-23b stem-loop Proteins 0.000 claims description 4
- 108091031298 miR-23b-1 stem-loop Proteins 0.000 claims description 4
- 108091082339 miR-23b-2 stem-loop Proteins 0.000 claims description 4
- 108091061970 miR-26a stem-loop Proteins 0.000 claims description 4
- 108091071822 miR-572 stem-loop Proteins 0.000 claims description 4
- 229960001156 mitoxantrone Drugs 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 claims description 4
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 4
- 229930003347 Atropine Natural products 0.000 claims description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 108091028080 MiR-132 Proteins 0.000 claims description 3
- 108091028049 Mir-221 microRNA Proteins 0.000 claims description 3
- 108700025695 Suppressor Genes Proteins 0.000 claims description 3
- 229940123237 Taxane Drugs 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229940022663 acetate Drugs 0.000 claims description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 229960000396 atropine Drugs 0.000 claims description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 108091074450 miR-200c stem-loop Proteins 0.000 claims description 3
- 108091045665 miR-202 stem-loop Proteins 0.000 claims description 3
- 108091031479 miR-204 stem-loop Proteins 0.000 claims description 3
- 108091032382 miR-204-1 stem-loop Proteins 0.000 claims description 3
- 108091085803 miR-204-2 stem-loop Proteins 0.000 claims description 3
- 108091089766 miR-204-3 stem-loop Proteins 0.000 claims description 3
- 108091073500 miR-204-4 stem-loop Proteins 0.000 claims description 3
- 108091053626 miR-204-5 stem-loop Proteins 0.000 claims description 3
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 3
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims description 3
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims description 3
- 108091061917 miR-221 stem-loop Proteins 0.000 claims description 3
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims description 3
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims description 3
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims description 3
- 108091088477 miR-29a stem-loop Proteins 0.000 claims description 3
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 claims description 3
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 claims description 3
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 claims description 3
- 108091031484 miR-335 stem-loop Proteins 0.000 claims description 3
- 108091048468 miR-383 stem-loop Proteins 0.000 claims description 3
- 108091044133 miR-454 stem-loop Proteins 0.000 claims description 3
- 108091063340 miR-497 stem-loop Proteins 0.000 claims description 3
- 108091031110 miR-539 stem-loop Proteins 0.000 claims description 3
- 108091063333 miR-556 stem-loop Proteins 0.000 claims description 3
- 108091038240 miR-638 stem-loop Proteins 0.000 claims description 3
- 108091063911 miR-650 stem-loop Proteins 0.000 claims description 3
- 108091092761 miR-671 stem-loop Proteins 0.000 claims description 3
- 108091034121 miR-92a stem-loop Proteins 0.000 claims description 3
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 claims description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 3
- 229960002087 pertuzumab Drugs 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- FVVPWVFWOOMXEZ-ZIADKAODSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-(4-propan-2-ylphenyl)but-1-enyl]phenol Chemical compound C=1C=C(C(C)C)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 FVVPWVFWOOMXEZ-ZIADKAODSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 2
- 108091027559 Mir-96 microRNA Proteins 0.000 claims description 2
- 108091033760 Oncomir Proteins 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims description 2
- 229960002258 fulvestrant Drugs 0.000 claims description 2
- 108091063986 let-7f stem-loop Proteins 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108091045790 miR-106b stem-loop Proteins 0.000 claims description 2
- 108091023403 miR-1202 stem-loop Proteins 0.000 claims description 2
- 108091054042 miR-1207 stem-loop Proteins 0.000 claims description 2
- 108091056924 miR-124 stem-loop Proteins 0.000 claims description 2
- 108091074816 miR-1268 stem-loop Proteins 0.000 claims description 2
- 108091046573 miR-1275 stem-loop Proteins 0.000 claims description 2
- 108091040501 miR-129 stem-loop Proteins 0.000 claims description 2
- 108091045757 miR-129-3 stem-loop Proteins 0.000 claims description 2
- 108091090758 miR-129-4 stem-loop Proteins 0.000 claims description 2
- 108091065139 miR-129-5 stem-loop Proteins 0.000 claims description 2
- 108091045872 miR-135 stem-loop Proteins 0.000 claims description 2
- 108091026523 miR-135a stem-loop Proteins 0.000 claims description 2
- 108091026375 miR-135b stem-loop Proteins 0.000 claims description 2
- 108091086065 miR-135b-2 stem-loop Proteins 0.000 claims description 2
- 108091031326 miR-15b stem-loop Proteins 0.000 claims description 2
- 108091069239 miR-17-2 stem-loop Proteins 0.000 claims description 2
- 108091023567 miR-1915 stem-loop Proteins 0.000 claims description 2
- 108091037787 miR-19b stem-loop Proteins 0.000 claims description 2
- 108091035428 miR-3143 stem-loop Proteins 0.000 claims description 2
- 108091036962 miR-3672 stem-loop Proteins 0.000 claims description 2
- 108091027983 miR-378-1 stem-loop Proteins 0.000 claims description 2
- 108091089716 miR-378-2 stem-loop Proteins 0.000 claims description 2
- 108091090987 miR-425 stem-loop Proteins 0.000 claims description 2
- 108091086430 miR-4324 stem-loop Proteins 0.000 claims description 2
- 108091069917 miR-491 stem-loop Proteins 0.000 claims description 2
- 108091090896 miR-506 stem-loop Proteins 0.000 claims description 2
- 108091045812 miR-544b stem-loop Proteins 0.000 claims description 2
- 108091076617 miR-544b-1 stem-loop Proteins 0.000 claims description 2
- 108091050743 miR-544b-2 stem-loop Proteins 0.000 claims description 2
- 108091069948 miR-548a-1 stem-loop Proteins 0.000 claims description 2
- 108091073707 miR-548a-2 stem-loop Proteins 0.000 claims description 2
- 108091034066 miR-548a-3 stem-loop Proteins 0.000 claims description 2
- 108091068733 miR-548e stem-loop Proteins 0.000 claims description 2
- 108091071062 miR-557 stem-loop Proteins 0.000 claims description 2
- 108091046865 miR-569 stem-loop Proteins 0.000 claims description 2
- 108091023843 miR-575 stem-loop Proteins 0.000 claims description 2
- 108091024411 miR-590 stem-loop Proteins 0.000 claims description 2
- 108091024127 miR-634 stem-loop Proteins 0.000 claims description 2
- 108091049434 miR-644 stem-loop Proteins 0.000 claims description 2
- 108091084058 miR-874 stem-loop Proteins 0.000 claims description 2
- 108091058491 miR-877 stem-loop Proteins 0.000 claims description 2
- 108091030513 miR-933 stem-loop Proteins 0.000 claims description 2
- 108091086713 miR-96 stem-loop Proteins 0.000 claims description 2
- 108091070961 miR-96-3 stem-loop Proteins 0.000 claims description 2
- 108091024443 miRa-135-1 stem-loop Proteins 0.000 claims description 2
- 229950008642 miproxifene Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229960004622 raloxifene Drugs 0.000 claims description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 2
- 229960005026 toremifene Drugs 0.000 claims description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 2
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims 2
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 108091091360 miR-125b stem-loop Proteins 0.000 claims 1
- 108091070946 miR-128 stem-loop Proteins 0.000 claims 1
- 108091032320 miR-146 stem-loop Proteins 0.000 claims 1
- 108091024530 miR-146a stem-loop Proteins 0.000 claims 1
- 108091087148 miR-20 stem-loop Proteins 0.000 claims 1
- 108091066984 miR-20-1 stem-loop Proteins 0.000 claims 1
- 108091076199 miR-20-2 stem-loop Proteins 0.000 claims 1
- 108091087149 miR-2171 stem-loop Proteins 0.000 claims 1
- 108091007432 miR-29b Proteins 0.000 claims 1
- 108091059493 miR-322 stem-loop Proteins 0.000 claims 1
- 108091049667 miR-340 stem-loop Proteins 0.000 claims 1
- 108091057189 miR-340-2 stem-loop Proteins 0.000 claims 1
- 108091029119 miR-34a stem-loop Proteins 0.000 claims 1
- 108091091625 miR-519c stem-loop Proteins 0.000 claims 1
- 108091026826 miR-519c-2 stem-loop Proteins 0.000 claims 1
- 108091032902 miR-93 stem-loop Proteins 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 115
- 239000000523 sample Substances 0.000 description 114
- 206010028980 Neoplasm Diseases 0.000 description 90
- 238000000338 in vitro Methods 0.000 description 82
- 206010006187 Breast cancer Diseases 0.000 description 79
- 208000026310 Breast neoplasm Diseases 0.000 description 79
- 201000011510 cancer Diseases 0.000 description 56
- 239000002250 absorbent Substances 0.000 description 40
- 230000002745 absorbent Effects 0.000 description 40
- 206010020718 hyperplasia Diseases 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 39
- 238000012216 screening Methods 0.000 description 39
- 102100027881 Tumor protein 63 Human genes 0.000 description 31
- 101710140697 Tumor protein 63 Proteins 0.000 description 30
- 101710087047 Cytoskeleton-associated protein 4 Proteins 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 26
- 238000003745 diagnosis Methods 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 201000010099 disease Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 238000004393 prognosis Methods 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 210000005075 mammary gland Anatomy 0.000 description 19
- 239000002609 medium Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 230000011987 methylation Effects 0.000 description 17
- 238000007069 methylation reaction Methods 0.000 description 17
- 239000007790 solid phase Substances 0.000 description 17
- 206010006256 Breast hyperplasia Diseases 0.000 description 16
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 15
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 15
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 15
- 238000012163 sequencing technique Methods 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 12
- 102400000050 Oxytocin Human genes 0.000 description 12
- 238000002648 combination therapy Methods 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 9
- 239000000020 Nitrocellulose Substances 0.000 description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229920001220 nitrocellulos Polymers 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 description 8
- 101710120841 Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 8
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 102000011782 Keratins Human genes 0.000 description 7
- 108010076876 Keratins Proteins 0.000 description 7
- 208000030270 breast disease Diseases 0.000 description 7
- 108700021293 carbetocin Proteins 0.000 description 7
- 229960001118 carbetocin Drugs 0.000 description 7
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 208000009458 Carcinoma in Situ Diseases 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 210000004883 areola Anatomy 0.000 description 6
- 208000024119 breast tumor luminal A or B Diseases 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 108700011259 MicroRNAs Proteins 0.000 description 5
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 5
- 208000010572 basal-like breast carcinoma Diseases 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 210000002777 columnar cell Anatomy 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 201000004933 in situ carcinoma Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091029523 CpG island Proteins 0.000 description 4
- 230000026641 DNA hypermethylation Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 3
- 108020005196 Mitochondrial DNA Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 208000028176 atypical lobular breast hyperplasia Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000005081 epithelial layer Anatomy 0.000 description 3
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 208000030776 invasive breast carcinoma Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000004223 overdiagnosis Methods 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000321096 Adenoides Species 0.000 description 2
- 108700020463 BRCA1 Proteins 0.000 description 2
- 102000036365 BRCA1 Human genes 0.000 description 2
- 101150072950 BRCA1 gene Proteins 0.000 description 2
- 108700020462 BRCA2 Proteins 0.000 description 2
- 102000052609 BRCA2 Human genes 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 101150008921 Brca2 gene Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000677545 Homo sapiens Long-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 2
- 101000710013 Homo sapiens Reversion-inducing cysteine-rich protein with Kazal motifs Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 2
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 101150020421 SFR2 gene Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 210000002534 adenoid Anatomy 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000001369 bisulfite sequencing Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 238000012350 deep sequencing Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 210000001703 glandular epithelial cell Anatomy 0.000 description 2
- 102000051957 human ERBB2 Human genes 0.000 description 2
- 230000006607 hypermethylation Effects 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 208000026535 luminal A breast carcinoma Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 150000002736 metal compounds Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 108091064355 mitochondrial RNA Proteins 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 238000000275 quality assurance Methods 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007841 sequencing by ligation Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BURHGPHDEVGCEZ-KJGLQBJMSA-N (e)-3-[4-[(e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-enyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(F)C=C(Cl)C=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(\C=C\C(O)=O)C=C1 BURHGPHDEVGCEZ-KJGLQBJMSA-N 0.000 description 1
- HYOAGWAIGJXNQH-UHFFFAOYSA-N 1-bromo-1-chloropropane Chemical compound CCC(Cl)Br HYOAGWAIGJXNQH-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 210000002925 A-like Anatomy 0.000 description 1
- 208000019738 Abnormality of the breast Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 102100032438 Beta-1,3-galactosyltransferase 1 Human genes 0.000 description 1
- 102100023993 Beta-1,3-galactosyltransferase 5 Human genes 0.000 description 1
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 102100024152 Cadherin-17 Human genes 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102100033772 Complement C4-A Human genes 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100037738 Fatty acid-binding protein, heart Human genes 0.000 description 1
- 102100028461 Frizzled-9 Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102100031493 Growth arrest-specific protein 7 Human genes 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 102100030308 Homeobox protein Hox-A11 Human genes 0.000 description 1
- 102100021090 Homeobox protein Hox-A9 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000792933 Homo sapiens AT-rich interactive domain-containing protein 4A Proteins 0.000 description 1
- 101000798380 Homo sapiens Beta-1,3-galactosyltransferase 1 Proteins 0.000 description 1
- 101000904597 Homo sapiens Beta-1,3-galactosyltransferase 5 Proteins 0.000 description 1
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 description 1
- 101000762247 Homo sapiens Cadherin-17 Proteins 0.000 description 1
- 101000710884 Homo sapiens Complement C4-A Proteins 0.000 description 1
- 101000710883 Homo sapiens Complement C4-B Proteins 0.000 description 1
- 101001027663 Homo sapiens Fatty acid-binding protein, heart Proteins 0.000 description 1
- 101001061405 Homo sapiens Frizzled-9 Proteins 0.000 description 1
- 101000923044 Homo sapiens Growth arrest-specific protein 7 Proteins 0.000 description 1
- 101001032092 Homo sapiens Histone deacetylase 9 Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101001083158 Homo sapiens Homeobox protein Hox-A11 Proteins 0.000 description 1
- 101000614439 Homo sapiens Keratin, type I cytoskeletal 15 Proteins 0.000 description 1
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000629400 Homo sapiens Mesoderm-specific transcript homolog protein Proteins 0.000 description 1
- 101001053641 Homo sapiens Plasma serine protease inhibitor Proteins 0.000 description 1
- 101000712958 Homo sapiens Ras association domain-containing protein 1 Proteins 0.000 description 1
- 101001112293 Homo sapiens Retinoic acid receptor alpha Proteins 0.000 description 1
- 101000756373 Homo sapiens Retinol-binding protein 1 Proteins 0.000 description 1
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 1
- 101000654740 Homo sapiens Septin-5 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000987003 Homo sapiens Tumor protein 63 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100039648 Lactadherin Human genes 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102100026821 Mesoderm-specific transcript homolog protein Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 108091027977 Mir-200 Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241001440127 Phyllodes Species 0.000 description 1
- 102100024078 Plasma serine protease inhibitor Human genes 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 102100033243 Ras association domain-containing protein 1 Human genes 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 102100022941 Retinol-binding protein 1 Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100037268 Secretoglobin family 3A member 1 Human genes 0.000 description 1
- 102100032744 Septin-5 Human genes 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010088412 Trefoil Factor-1 Proteins 0.000 description 1
- 102000008817 Trefoil Factor-1 Human genes 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- CNKHSLKYRMDDNQ-UHFFFAOYSA-N halofenozide Chemical compound C=1C=CC=CC=1C(=O)N(C(C)(C)C)NC(=O)C1=CC=C(Cl)C=C1 CNKHSLKYRMDDNQ-UHFFFAOYSA-N 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 108091091807 let-7a stem-loop Proteins 0.000 description 1
- 108091057746 let-7a-4 stem-loop Proteins 0.000 description 1
- 108091028376 let-7a-5 stem-loop Proteins 0.000 description 1
- 108091024393 let-7a-6 stem-loop Proteins 0.000 description 1
- 108091091174 let-7a-7 stem-loop Proteins 0.000 description 1
- 108091007423 let-7b Proteins 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000026534 luminal B breast carcinoma Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MCPLVIGCWWTHFH-UHFFFAOYSA-L methyl blue Chemical compound [Na+].[Na+].C1=CC(S(=O)(=O)[O-])=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[NH+]C=2C=CC(=CC=2)S([O-])(=O)=O)C=2C=CC(NC=3C=CC(=CC=3)S([O-])(=O)=O)=CC=2)C=C1 MCPLVIGCWWTHFH-UHFFFAOYSA-L 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 108091027943 miR-16 stem-loop Proteins 0.000 description 1
- 108091035328 miR-217 stem-loop Proteins 0.000 description 1
- 108091039135 miR-217-1 stem-loop Proteins 0.000 description 1
- 108091029206 miR-217-2 stem-loop Proteins 0.000 description 1
- 108091048549 miR-29b stem-loop Proteins 0.000 description 1
- 108091092564 miR-494 stem-loop Proteins 0.000 description 1
- 108091030941 miR-554 stem-loop Proteins 0.000 description 1
- 108091050734 miR-652 stem-loop Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 102000041788 p53 family Human genes 0.000 description 1
- 108091075611 p53 family Proteins 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000035803 proliferative type breast fibrocystic change Diseases 0.000 description 1
- 230000019639 protein methylation Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002978 thoracic duct Anatomy 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462007830P | 2014-06-04 | 2014-06-04 | |
| US62/007,830 | 2014-06-04 | ||
| PCT/US2015/033827 WO2015187727A2 (en) | 2014-06-04 | 2015-06-02 | Molecular mammography |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527775A JP2017527775A (ja) | 2017-09-21 |
| JP2017527775A5 JP2017527775A5 (enExample) | 2018-07-12 |
| JP6757935B2 true JP6757935B2 (ja) | 2020-09-23 |
Family
ID=54767566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570087A Expired - Fee Related JP6757935B2 (ja) | 2014-06-04 | 2015-06-02 | 分子マンモグラフィ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170145515A1 (enExample) |
| EP (1) | EP3152579A4 (enExample) |
| JP (1) | JP6757935B2 (enExample) |
| CN (1) | CN107076747B (enExample) |
| WO (1) | WO2015187727A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107012199A (zh) * | 2016-01-28 | 2017-08-04 | 上海市东方医院 | 一种在血浆和血清中检测miRNA的方法 |
| JP6980219B2 (ja) * | 2016-08-22 | 2021-12-15 | いであ株式会社 | がんを検出、又はがんの進行期を判定する方法 |
| CA3044257A1 (en) * | 2016-11-22 | 2018-05-31 | Prime Genomics, Inc. | Methods for cancer detection |
| EP3681491A4 (en) | 2017-09-11 | 2021-06-30 | Atossa Therapeutics, Inc. | PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES |
| JP7108715B2 (ja) * | 2018-01-25 | 2022-07-28 | パー ホール | 乳房障害の治療をモニターするための組成物および方法 |
| GB201907999D0 (en) * | 2019-06-05 | 2019-07-17 | Cambridge Entpr | Breast cancer detection methods |
| WO2021003433A1 (en) | 2019-07-03 | 2021-01-07 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
| CN110760513A (zh) * | 2019-08-23 | 2020-02-07 | 西北工业大学 | 靶向三阴性乳腺癌细胞PENK基因的miR-506及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798266A (en) * | 1996-08-27 | 1998-08-25 | K-Quay Enterprises, Llc | Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer |
| WO2003042660A2 (en) * | 2001-11-14 | 2003-05-22 | Sirbasku David A | Screening method for predicting susceptibility to breast cancer |
| WO2003077871A2 (en) * | 2002-03-15 | 2003-09-25 | Cytyc Health Corporation | Method of diagnosis and treatment of breast lesions |
| WO2007140352A2 (en) * | 2006-05-26 | 2007-12-06 | Invitrogen Corporation | Plasma membrane and secreted cancer biomarkers |
| EP2217143A4 (en) * | 2007-12-11 | 2015-04-15 | Epi Sci Llc | ELECTRIC BIOIMPEDANZ ANALYSIS AS A BIOMARKER OF BREAST DENSITY AND / OR BREAST CANCER RISK |
| JP2012507300A (ja) * | 2008-10-30 | 2012-03-29 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | Ｒｎａパターンを評価する方法 |
| EP2350320A4 (en) * | 2008-11-12 | 2012-11-14 | Caris Life Sciences Luxembourg Holdings | METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES |
| WO2011137288A2 (en) * | 2010-04-30 | 2011-11-03 | The Ohio State University | Mirna networks in cancers and leukemias and uses thereof |
| CA2853343A1 (en) * | 2011-10-24 | 2013-05-02 | Atossa Genetics, Inc. | Absorbent paper and use thereof for breast cancer detection |
| US20140255954A1 (en) * | 2011-10-24 | 2014-09-11 | Atossa Genetics, Inc. | Method of breast cancer detection |
-
2015
- 2015-06-02 EP EP15803028.8A patent/EP3152579A4/en not_active Withdrawn
- 2015-06-02 WO PCT/US2015/033827 patent/WO2015187727A2/en not_active Ceased
- 2015-06-02 JP JP2016570087A patent/JP6757935B2/ja not_active Expired - Fee Related
- 2015-06-02 CN CN201580039837.XA patent/CN107076747B/zh not_active Expired - Fee Related
- 2015-06-02 US US15/316,136 patent/US20170145515A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017527775A (ja) | 2017-09-21 |
| US20170145515A1 (en) | 2017-05-25 |
| CN107076747A (zh) | 2017-08-18 |
| EP3152579A4 (en) | 2018-01-17 |
| WO2015187727A3 (en) | 2016-01-21 |
| EP3152579A2 (en) | 2017-04-12 |
| CN107076747B (zh) | 2021-02-02 |
| WO2015187727A2 (en) | 2015-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ou et al. | Single‐nucleus RNA sequencing and spatial transcriptomics reveal the immunological microenvironment of cervical squamous cell carcinoma | |
| Ning et al. | Early diagnosis of lung cancer: which is the optimal choice? | |
| CN107076747B (zh) | 分子乳房摄影术 | |
| Zhang et al. | Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes? | |
| EP2809801B1 (en) | Non-invasive cancer diagnosis | |
| Takeshita et al. | Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma | |
| US7888035B2 (en) | Methods for assessing RNA patterns | |
| Jovčevska | Sequencing the next generation of glioblastomas | |
| JP2019528081A (ja) | 子宮内膜症についてのバイオマーカーとしてのマイクロｒｎａ | |
| WO2016109939A1 (zh) | 一种富集循环肿瘤dna的方法和试剂 | |
| Andreasen | Molecular features of adenoid cystic carcinoma with an emphasis on microRNA expression. | |
| WO2013057567A1 (en) | Biomarkers useful for detection of types, grades and stages of human breast cancer | |
| Senaratne et al. | Clinical value of circulating microRNAs in diagnosis and prognosis of pancreatic cancer: A systematic review | |
| Delmonico et al. | Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions | |
| Azumi et al. | MiR-575 in exosomes of vaginal discharge is downregulated in ovarian cancer patients | |
| Nafar et al. | An investigation into cell-free DNA in different common cancers | |
| JP2011511635A (ja) | 癌標識としての結腸癌関連転写因子１（ｃｃａｔ−１） | |
| CN103773761B (zh) | 检测胃癌的血清/血浆微小rna标志物及其应用 | |
| Attia et al. | Altered expression of microRNAs in the bone marrow of multiple myeloma patients and their relationship to cytogenetic aberrations | |
| Gordon et al. | Genomic medicine for cancer diagnosis | |
| Pal et al. | Biomarkers as putative therapeutic targets in colorectal cancer | |
| Bajpai et al. | Biomarkers of Esophageal Cancers and Precancerous Lesions | |
| Zambelli | Analisi molecolare di forme aggressive di neoplasia endocrina per la identificazione di meccanismi di progressione e di potenziali nuovi bersagli terapeutici | |
| Tassistro | Caratterizzazione delle vescicole extracellulari e del loro profilo di espressione dei microRNA nel midollo osseo di pazienti con neuroblastoma ad alto rischio | |
| CN120789258A (zh) | Pde4dip作为生物标志物在制备用于辅助治疗肾脏足细胞损伤及足细胞病的药剂盒和药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180530 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190806 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200417 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200612 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200727 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200821 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6757935 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |